Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1890 - Incidence, epidemiology and outcome in adults and children with ALL: A review of population-based cancer registries (PBCRs), an experience from Eastern India


09 Oct 2016


Poster display


Sangita Banerjee


Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377


S. Banerjee

Author affiliations

  • Clinical Research, University of Calcutta, 700034 - Kolkata/IN


Abstract 1890


Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. With the introduction of a classification system for hematopoietic and lymphoid neoplasms, assessment of ALL epidemiology is now possible. Our aim is to provide an updated overview of the incidence of cancer on the basis of the report from the National Cancer Registry Program (NCRP) for the years 2006- 2015 that covered population aged 0 to 64 years.


The NCRP report (2013) provides data from PBCRs covering 70.45% of the state's population aged (0-75) years. Age-specific incidence data for ALL and data for incidence-mortality rates were collected. Based on Age-adjusted cancer incidence rates for children aged 0-14years were collected.


With significant age-related variations (0.53 at 40–65years, ∼1.0 at 54–73 years), overall survival (68%; 33%) or event-free survival (46%, 29%) with respective age groups, overall survival (OS) improved from 29.8% in the years 2000–2005 to 41.1% in 2010–2015 (P 48%), OS was 5 cases per 0.1 million per year), with rates increasing more than 10 cases per 0.1 million by age 8 years. ALL among children aged 2 to 3 years is greater than that for infants and children aged 10 years and older. Cancer incidence AARpm is 28.6189.6 between age (0.58.8) years.


Childhood cancer contribute to 5.6% to 13.8% of all cancers (CCI as 5 to 15 per 0.1 million) in India for the years 2010-2015. Among children with ALL, more than 95% attain remission, 80% of patients aged 1 to 18 years with newly diagnosed ALL treated on current regimens are expected to be long-term event-free survivors. Childhood cancer in developing countries are increasing and sharper differences are seen than those of western countries due to exposures during prenatal development in low and middle income countries.

Clinical trial identification

Legal entity responsible for the study

Sangita Banerjee




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings